RESEARCH ARTICLE

Association between hepatic oxygenation on near-infrared spectroscopy and clinical factors in patients undergoing hemodialysis

Yuichiro Ueda1☯, Susumu Ookawara1☯*, Kiyonori Ito1☯, Yusuke Sasabuchi2, Hideyuki Hayasaka3, Masaya Kofuji2, Takayuki Uchida3, Sojiro Imai4, Satoshi Kiryu4, Saori Minato1, Haruhisa Miyazawa1, Hidenori Sanayama5, Keiji Hirai1, Kaoru Tabei4, Yoshiyuki Morishita1

1 Division of Nephrology, Department of Integrated Medicine, Saitama Medical Center, Jichi Medical University, Saitama, Japan, 2 Data Science Center, Jichi Medical University, Tochigi, Japan, 3 Department of Clinical Engineering, Saitama Medical Center, Jichi Medical University, Saitama, Japan, 4 Department of Dialysis, Minami-Uonuma City Hospital, Niigata, Japan, 5 Division of Neurology, Department of Integrated Medicine, Saitama Medical Center, Jichi Medical University, Saitama, Japan

☯ These authors contributed equally to this work.
* su-ooka@hb.tp1.jp

Abstract

The hepato-splanchnic circulation directly influences oxygenation of the abdominal organs and plays an important role in compensating for the blood volume reduction that occurs in the central circulation during hemodialysis (HD) with ultrafiltration. However, the hepato-splanchnic circulation and oxygenation cannot be easily evaluated in the clinical setting of HD therapy. We included 185 HD patients and 15 healthy volunteers as the control group in this study. Before HD, hepatic regional oxygen saturation (rSO2), a marker of hepatic oxygenation reflecting the hepato-splanchnic circulation and oxygenation, was monitored using an INVOS 5100c oxygen saturation monitor. Hepatic rSO2 was significantly lower in patients undergoing HD than in healthy controls (56.4 ± 14.9% vs. 76.2 ± 9.6%, p < 0.001). Multivariable regression analysis showed that hepatic rSO2 was independently associated with body mass index (BMI; standardized coefficient: 0.294), hemoglobin (Hb) level (standardized coefficient: 0.294), a history of cardiovascular disease (standardized coefficient: -0.157), mean blood pressure (BP; standardized coefficient: 0.154), and serum albumin concentration (standardized coefficient: 0.150) in Model 1 via a simple linear regression analysis. In Model 2 using the colloid osmotic pressure (COP) in place of serum albumin concentration, the COP (standardized coefficient: 0.134) was also identified as affecting hepatic rSO2.

Basal hepatic oxygenation before HD might be affected by BMI, Hb levels, a history of cardiovascular disease, mean BP, serum albumin concentration, and the COP. Further prospective studies are needed to clarify whether changes in these parameters, including during HD, affect the hepato-splanchnic circulation and oxygenation in HD patients.
Introduction

Body fluid management is an important aspect of hemodialysis (HD), and ultrafiltration is essential in achieving each patient’s target body weight. During HD with ultrafiltration, blood shifting from the hepato-splanchnic circulation to the central circulation plays an important role in compensating for the blood volume reduction and decrease in cardiac output and blood pressure (BP) \cite{1,2}, in addition to fluid moving from the interstitium to the intravascular space. Therefore, the hepato-splanchnic circulation in patients undergoing HD has been attracting increasing attention \cite{3,4}. However, the hepato-splanchnic circulation status cannot be easily evaluated in the clinical setting of HD therapy.

Near-infrared spectroscopy has been used to measure regional oxygen saturation (rSO$_2$), a marker of tissue oxygenation \cite{5,6}, to detect imbalances between arterial oxygen delivery and tissue oxygen consumption. The hepatic circulation consists of two different blood supplies, one from the hepatic artery and the other from the portal vein \cite{7} and monitoring hepatic oxygenation would help capture important changes in oxygen distribution to the hepato-splanchnic circulation \cite{8}. Hepatic rSO$_2$ values, which were recently used to evaluate the hepato-splanchnic circulation and oxygenation of patients undergoing HD, were reportedly maintained during HD without intradialytic hypotension \cite{9}, and significantly increased in response to an increase in hemoglobin (Hb) level by intradialytic blood transfusion \cite{10}. Additionally, a decrease in hepatic rSO$_2$ was confirmed prior to intradialytic hypotension during HD \cite{11,12}. However, few reports have examined the association between hepatic rSO$_2$ before HD and clinical factors in patients undergoing HD, and the clinical factors that affect hepatic rSO$_2$ remain unknown. Clarification of these factors might provide guidance for maintaining or improving patient hepato-splanchnic circulation and oxygenation status in the clinical setting of HD therapy. Therefore, this study aimed to elucidate the clinical factors influencing hepatic rSO$_2$ in patients undergoing HD.

Materials and methods

Participants

This study was performed at two facilities, including our hospital. Patients who met the following criteria were enrolled: (i) age $>$ 20 years; (ii) end-stage renal disease managed with HD; (iii) started HD at least one month before the study; (iv) tissue thickness $\leq$ 20 mm from the skin to the surface of the liver in the right intercostal area as measured by ultrasonography; and (v) hepatic rSO$_2$ data collected using an INVOS 5100c oxygen saturation monitor. The exclusion criteria were coexisting major diseases, including congestive heart failure or neurological disorders, such as severe cerebrovascular disease and cognitive impairment.

Fig 1 shows a flow chart of patient enrollment and analysis. Of the 277 patients screened, 224 met the inclusion criteria and were enrolled between August 1, 2013 and December 31, 2019. Overall, 39 patients were excluded from the analysis because of lack of data. Ultimately, 185 patients (24 from Minami-Uonuma City Hospital and 161 from our hospital) were included and analyzed in the present study. In addition, 15 healthy volunteers (nine men and six women; mean age, 38.2 ± 17.8 years) were recruited as a control group.

Ethics approval

All participants provided written informed consent. The study was approved by the Institutional Review Board of the Saitama Medical Center at Jichi Medical University (Saitama, Japan: approval numbers, RIN 15–104 and RINS19–HEN007) and Minami-Uonuma City
Hospital (Niigata, Japan; approval number, H29-11) and conformed to the provisions of the Declaration of Helsinki (as revised in Tokyo in 2004).

Patients’ baseline characteristics and clinical laboratory measurements
The patients’ baseline characteristics and clinical data were collected from their medical charts, while data on the primary disease leading to the need for dialysis and the coexistence of comorbid cardiovascular or cerebrovascular diseases were extracted from their medical records. BP and heart rate were measured before HD with the patients in the supine position. Blood samples were obtained at ambient temperatures from the HD access points, such as arteriovenous fistulas, arteriovenous grafts, and HD catheters, from all the patients before HD. Peripheral blood counts and biochemical parameters were evaluated in all the patients.

Monitoring of hepatic oxygenation
Hepatic rSO₂, a marker of hepatic oxygenation, was monitored using the INVOS 5100c saturation monitor (Covidien Japan, Tokyo, Japan) described previously [10]. Briefly, this instrument uses a light-emitting diode that transmits near-infrared light at two wavelengths (735 and 810 nm) and two silicon photodiodes that act as light detectors that measure oxygenated and deoxygenated hemoglobin (Hb). The ratio of the signal strengths of the oxygenated Hb and the total Hb (oxygenated Hb + deoxygenated Hb) was calculated, and the corresponding percentage was recorded as a single numerical value that represented the rSO₂ [5,6]. All data obtained using this instrument were immediately and automatically stored. Furthermore, the light paths leading from the emitter to the different detectors share a common part: the
30-mm detector assesses superficial tissue, whereas the 40-mm detector assesses deep tissue. By analyzing the differential signals collected by the two detectors, cerebral rSO$_2$ values in the deep tissue were obtained from a distance of 20–30 mm from the body surface [13,14]. These measurements were performed at 6-s intervals.

Prior to HD, the participants rested in the supine position for at least 10 min to reduce the influence of postural changes on rSO$_2$. An rSO$_2$ measuring sensor was attached to each patient’s right intercostal area above the liver to measure the resting-state rSO$_2$ levels. The right intercostal area just above the liver was identified on ultrasonography before HD. The rSO$_2$ level was measured for 5 min before HD, and the mean rSO$_2$ value was calculated as a measure of cerebral oxygenation in each patient.

### Calculation of colloid osmotic pressure

Intravascular colloid osmotic pressure (COP) is important for maintaining the systemic tissue microcirculation. Therefore, to examine the influence of the COP on hepatic rSO$_2$, the COP before HD was calculated using the equation below (a specialized method for HD patients) [15]:

$$
\text{COP (mmHg)} = -7.91 + 5.64 \times \text{serum albumin (g/dL)} + 3.00 \times \left[ \text{total protein (g/dL)} - \text{serum albumin (g/dL)} \right]
$$

### Statistical analysis

Data are expressed as mean ± standard deviation or median and interquartile range. The normality of the hepatic rSO$_2$ in each of the HD patient and healthy control groups was assessed using the Shapiro-Wilk test. The results of hepatic rSO$_2$ in each group were not significant (hepatic rSO$_2$ in HD patients, p = 0.185; healthy control, p = 0.236). Therefore, hepatic rSO$_2$ distribution in each group was confirmed to be normal. The differences in hepatic rSO$_2$ levels between healthy controls and patients undergoing HD were evaluated using the unpaired Student’s t-test. Variables with P-values < 0.05 in a simple linear regression analysis were included in the multivariable linear regression analysis to identify factors affecting hepatic rSO$_2$ in patients undergoing HD. HD duration and C-reactive protein (CRP) levels were transformed using the natural logarithm (Ln) in the regression analyses because they had a skewed distribution. All analyses were performed using IBM SPSS Statistics for Windows, version 26.0 (IBM, Armonk, NY, USA). Statistical significance was set at P < 0.05.

### Results

The patients’ general characteristics and the correlations between hepatic rSO$_2$ and clinical parameters are summarized in Table 1. The mean hepatic rSO$_2$ was significantly lower in patients undergoing HD than in healthy controls (56.4 ± 14.9% vs. 76.2 ± 9.6%, p < 0.001; Fig 2). Furthermore, hepatic rSO$_2$ was significantly positively correlated with body mass index (BMI), mean BP, interdialytic weight gain, Hb levels, the serum creatinine concentration, the serum albumin concentration, the colloid osmotic pressure, and the use of renin-angiotensin-aldosterone system (RAS) inhibitors and calcium channel blockers and negatively correlated with age, a history of cardiovascular disease, the aspartate aminotransferase level, and Ln-CRP levels.

The results of the multivariable linear regression analysis are presented in Tables 2 and 3. For Model 1, age, BMI, the mean BP, a history of cardiovascular disease, Hb levels, the serum
creatinine concentration, the serum albumin concentration, the aspartate aminotransferase level, Ln-CRP levels, and the use of RAS inhibitors and calcium channel blockers, as variables with P values < 0.05, were included in the multivariable linear regression analysis. As shown in Table 2, hepatic rSO₂ was independently associated with BMI (standardized coefficient: 0.294), Hb levels (standardized coefficient: 0.294), a history of cardiovascular disease (standardized coefficient: -0.157), the mean BP (standardized coefficient: 0.154), and the serum albumin concentration (standardized coefficient: 0.150). The COP value was included in place.
Fig 2. Comparison of hepatic rSO\(_2\) between patients undergoing HD and healthy controls. Abbreviations: HD, hemodialysis; rSO\(_2\), regional saturation of oxygen. *p < 0.001 vs. healthy controls.

https://doi.org/10.1371/journal.pone.0259064.g002

Table 2. Multivariable linear regression analysis in Model 1 using serum albumin: Factors independently associated with hepatic rSO\(_2\) in patients undergoing HD.

| Variables                              | Coefficient | 95% CI   | Standardized coefficient | P      |
|----------------------------------------|-------------|----------|--------------------------|--------|
| Age                                    | -0.022      |          |                          | 0.713  |
| Body mass index                        | 1.667       | 1.175–3.770 | 0.294              | < 0.001*|
| Mean BP                                | 0.145       | 0.035–0.255 | 0.154              | 0.010* |
| History of cardiovascular disease      | -4.906      | -8.317 to -1.494 | -0.157            | 0.005* |
| Interdialytic weight gain              | 0.054       |          |                          | 0.351  |
| Hemoglobin                             | 2.668       | 1.566–3.770 | 0.294              | < 0.001*|
| Serum creatinine                       | 0.105       |          |                          | 0.095  |
| Serum albumin                          | 4.114       | 0.017–0.760 | 0.150              | 0.017* |
| AST                                    | -0.040      |          |                          | 0.485  |
| Ln-CRP                                 | -0.056      |          |                          | 0.413  |
| Use of RAS inhibitors                  | 0.044       |          |                          | 0.437  |
| Use of calcium channel blockers        | 0.086       |          |                          | 0.133  |

*Statistically significant.

AST, aspartate aminotransferase; BP, blood pressure; CI, confidence interval; CRP, C-reactive protein; HD, hemodialysis; Ln, natural logarithm; RAS, renin-angiotensin-aldosterone system; rSO\(_2\), regional oxygen saturation.

https://doi.org/10.1371/journal.pone.0259064.t002
of serum albumin concentration in Model 2 to avoid collinearity with the serum albumin concentration. As a result, the COP (standardized coefficient: 0.134) was also identified as factors affecting hepatic rSO\textsubscript{2} in addition to BMI (standardized coefficient: 0.377), Hb levels (standardized coefficient: 0.301), a history of cardiovascular disease (standardized coefficient: -0.166), and the mean BP (standardized coefficient: 0.161) (Table 3).

### Discussion

In this study, a significant decrease in hepatic rSO\textsubscript{2} was confirmed in patients undergoing HD compared to healthy controls. In addition, hepatic rSO\textsubscript{2} levels were independently associated with BMI, Hb levels, a history of cardiovascular disease, the mean BP, the serum albumin concentration, and the COP on the multivariable linear regression analysis. We confirmed that each adjusted R\textsuperscript{2} reflects the fitness of model; those in Models 1 and 2 were 0.455 and 0.452, respectively. Therefore, these results are in the range of moderately good results for an exploratory study.

A difference in hepatic rSO\textsubscript{2} between patients undergoing HD and healthy controls was also confirmed in this study. Thus far, significant decreases in cerebral oxygenation in patients undergoing HD compared with healthy controls have been reported [16–18] that might be explained by renal anemia and a decrease in the serum albumin concentration [17,18]. Therefore, the results of this study are consistent with those of previous reports of tissue oxygenation in patients undergoing HD, although this result was inconclusive because the ages and sexes were not completely matched between the groups.

In the present study, BMI was the most significantly positive factor associated with hepatic rSO\textsubscript{2}. In patients undergoing HD, in contrast to the general population, a higher BMI was reportedly associated with better survival, a phenomenon referred to as reverse epidemiology [19,20]. Serum leptin is reportedly associated with reverse epidemiology in patients undergoing HD [21–23]. Serum leptin has emerged as a potential risk factor for cardiovascular disease due to its proinflammatory, proatherogenic, and prothrombotic effects, which promote endothelial dysfunction [24]. However, in patients undergoing HD, the serum leptin concentration

---

**Table 3. Multivariable linear regression analysis in Model 2 using colloid osmotic pressure: Factors independently associated with hepatic rSO\textsubscript{2} in patients undergoing HD.**

| Variables                        | Coefficient | 95% CI          | Standardized coefficient | P       |
|----------------------------------|-------------|-----------------|--------------------------|---------|
| Age                              | -0.028      | 0.645           | 0.377                    | < 0.001*|
| Body mass index                  | 1.671       | 1.179–2.164     | 0.161                    | 0.007*  |
| Mean BP                          | 0.151       | 0.041–0.261     | -0.166                   | 0.003*  |
| History of cardiovascular disease| -5.183      | -8.615 to -1.751| -0.166                   | 0.003*  |
| Interdialytic weight gain        | 0.044       | 0.446           |                          |         |
| Hemoglobin                       | 2.726       | 1.625–3.826     | 0.301                    | < 0.001*|
| Serum creatinine                 | 0.111       | 0.075           |                          |         |
| Colloid osmotic pressure         | 0.686       | 0.029–0.072     | 0.134                    | 0.029*  |
| AST                              | -0.048      | 0.408           |                          |         |
| Ln-CRP                           | -0.079      | 0.221           |                          |         |
| Use of RAS inhibitors            | 0.043       | 0.454           |                          |         |
| Use of calcium channel blockers  | 0.088       | 0.128           |                          |         |

*Statistically significant.

AST, aspartate aminotransferase; BP, blood pressure; CI, confidence interval; CRP, C-reactive protein; HD, hemodialysis; Ln, natural logarithm; RAS, renin-angiotensin-aldosterone system; rSO\textsubscript{2}, regional oxygen saturation.

https://doi.org/10.1371/journal.pone.0259064.t003
was significantly and positively correlated with BMI [25] and negatively associated with serum CRP [26] and Malnutrition-Inflammation Score [22]. Furthermore, there was a significant positive association between the serum leptin concentration and cardiac function [23]. Therefore, according to the increase in BMI, a serum leptin concentration increase might be expected and positively influence the hepato-splanchnic circulation by improving cardiac function. However, serum leptin concentrations were not measured in the present study. Therefore, we cannot directly comment on the effect of serum leptin on the association between hepatic oxygenation and BMI.

Hb plays an important role in carrying oxygen to the systemic tissues, including the liver; therefore, systemic oxygenation is believed to be associated with the Hb level. The hepatic rSO₂ of patients with severe anemia undergoing HD was low, but it improved significantly in response to the increase in Hb following an intradialytic blood transfusion (hepatic rSO₂, from 46.7 ± 1.7% to 55.4 ± 2.0% before versus after intradialytic blood transfusion), and changes in hepatic rSO₂ were positively and significantly associated with the transfusion-induced Hb increase [10]. In this study, similar to the association between hepatic rSO₂ and BMI, the Hb level had a significant positive effect on hepatic oxygenation. Therefore, Hb levels targeted in the clinical setting of HD therapy, which was considered the upper limit for the appropriate management of renal anemia [27–29], would contribute to maintaining and/or improving the hepato-splanchnic circulation and oxygenation of patients undergoing HD. In addition, the hepatic artery buffer response, which is increased in the hepatic artery flow to compensate for the reduction of portal vein flow, plays an important role in maintaining hepatic circulation under various clinical conditions [30,31]. However, beyond the protective effect of the hepatic artery buffer response, prolonged decreases in the cardiac output and mean BP induced by cardiac tamponade are reportedly associated with a decreased blood flow in the hepatic artery [32], which would lead to a decrease in hepatic oxygenation. Furthermore, hepatic rSO₂ values were significantly correlated with cardiac output, systolic BP, and diastolic BP [8]. In this study, the mean BP showed a significantly positive influence on hepatic rSO₂, whereas a history of cardiovascular disease was negatively associated with hepatic rSO₂. Although this study did not confirm the influence of a history of cardiovascular disease on cardiac function, it might be associated with a decrease in cardiac output in patients undergoing HD. Therefore, the result of a negative association with a history of cardiovascular disease and a positive association with mean BP on hepatic oxygenation might be consistent with those of previous reports [8,32]. Serum albumin represents an oncotic and non-oncotic effect, including the formation of COP and anti-oxidant and anti-inflammatory properties [33–35]. In particular, an increase in the serum albumin concentration reportedly improved cerebral oxygenation by improving the cerebral microcirculation associated with the oncotic pressure effect [18]. In this study, the serum albumin concentration and COP were analyzed in separate models to determine whether the association between hepatic oxygenation and the serum albumin concentration was due to the effect of the oncotic pressure effect. The results of this study showed that serum albumin concentration and COP were significantly and positively correlated with hepatic rSO₂. Therefore, the effect of serum albumin on hepatic oxygenation might be at least partially associated with the oncotic pressure effect influenced by the serum albumin concentration in patients undergoing HD.

The present study had several limitations. First, its sample size was relatively small. Second, the history of cardiovascular diseases was extracted from the patients’ medical records, and cardiac functions was not always confirmed using echocardiography. However, the assessment of cardiac function via echocardiography would be essential to clarify the association between the clinical history and stages of cardiovascular disease, and the status of hepato-splanchnic circulation, including hepatic rSO₂. Therefore, further evaluation of this study, including the
assessments of cardiac function via echocardiography as a confounding factor, would be required. Third, the residual renal function and diuresis play an important role in the body fluid management of HD patients via the prevention of interdialytic weight gain, which may lead to the reduction in the need for aggressive ultrafiltration and the stability in hepato-splanchnic circulation. Furthermore, because of the increases in urinary volume and sodium excretion associated with the usage of furosemide even in HD patients [36], it is important to check the usage of diuretics. However, residual diuresis volume was not measured, and the diuretics usage was not quantified in this study. Therefore, the association between hepatic rSO₂ and the residual renal function, including diuresis, remains unclear. Fourth, the type of dialysis modality and differences in dialyzer membrane may influence the hepatic rSO₂ values due to the increase of albumin loss into the dialysate and decrease in serum albumin concentration [37,38]. Information regarding the dialyzer membrane was not collected in this study, although the only method of dialysis was HD for all patients included in this study. The differences in dialysis modalities and dialysis membranes may affect the hepatic oxygenation; hence, further studies are needed. In addition, regarding the patients’ characteristics in this study, the mean age in this study was 68.3 ± 10.9 years, while that in Japanese dialysis patients was reportedly 68.75 years [39]. Furthermore, 41% and 23% of the causes of chronic renal failure in this study were diabetes mellitus and chronic glomerulonephritis, respectively, while these two causes were reported as 39.0% and 26.8% in Japanese patients, respectively [39]. Therefore, the age and causes of chronic renal failure in this study could be considered similar to those in Japanese dialysis patients. However, the median HD duration in this study was 0.7 years, while the mean dialysis period in Japanese patients was 6.82 years [39]. Based on these characteristics in this study, the shortness of HD duration in this study compared with those in Japanese dialysis patients may have affected the hepatic oxygenation status. Finally, since the present study had a cross-sectional design, it was impossible to assess the directionality of the association between hepatic oxygenation and clinical factors. Therefore, future studies are required to comprehensively investigate the association between hepatic rSO₂ and clinical parameters.

**Conclusion**

The hepatic oxygenation before HD might be positively associated with the Hb level, mean BP, serum albumin concentration, and COP as well as BMI and a history of cardiovascular disease. Further prospective studies are needed to clarify whether changes in these parameters, including during HD, affect the hepato-splanchnic circulation and oxygenation of patients undergoing HD.

**Supporting information**

**S1 Dataset.**

(XLSX)

**Acknowledgments**

We thank the study participants and dialysis staff of Minami-Uonuma City Hospital and our hospital.

**Author Contributions**

**Conceptualization:** Yuichiro Ueda, Susumu Ookawara, Kiyonori Ito.

**Data curation:** Yuichiro Ueda, Susumu Ookawara.
Formal analysis: Susumu Ookawara, Kiyonori Ito, Yusuke Sasabuchi.

Funding acquisition: Susumu Ookawara.

Investigation: Yuichiro Ueda, Susumu Ookawara, Kiyonori Ito, Hideyuki Hayasaka, Masaya Kofuji, Takayuki Uchida, Sojiro Imai, Satoshi Kiryu, Saori Minato, Haruhisa Miyazawa, Hidenori Sanayama, Keiji Hirai.

Methodology: Yuichiro Ueda, Susumu Ookawara, Kiyonori Ito.

Project administration: Susumu Ookawara.

Supervision: Kaoru Tabei, Yoshiyuki Morishita.

Validation: Yuichiro Ueda, Susumu Ookawara, Kiyonori Ito.

Writing – original draft: Yuichiro Ueda, Susumu Ookawara, Kiyonori Ito.

References

1. Yu AW, Nawab ZM, Barnes WE, Lai KN, Ing TS, Daugirdas JT. Splanchnic erythrocyte content decreases during hemodialysis: a new compensatory mechanism for hypovolemia. Kidney Int. 1997; 51: 1986–1990. https://doi.org/10.1038/ki.1997.270 PMID: 9186892

2. Ribitsch W, Schneditz D, Franssen CFM, Schlcher G, Stadlbauer V, Horina JH, et al. Increased hepato-splanchnic vasoconstriction in diabetics during regular hemodialysis. PLoS ONE. 2015; 10: e0145411. https://doi.org/10.1371/journal.pone.0145411 PMID: 26713734

3. Daugirdas JT. Pathophysiology of dialysis hypotension: an update. Am J Kidney Dis. 2001; 4(Suppl 4): S11–S17. https://doi.org/10.1053/ajkd.2001.28090 PMID: 11602456

4. Daugirdas JT. Intradialytic hypotension and splanchnic shifting: integrating an overlooked mechanism with the detection of ischemia-related signals during hemodialysis. Semin Dial. 2019; 32: 243–247. https://doi.org/10.1111/sdi.12781 PMID: 30864293

5. Tobias JD. Cerebral oxygenation monitoring: near-infrared spectroscopy. Expert Rev Med Devices. 2006; 3: 235–243. https://doi.org/10.1586/17434440.3.2.235 PMID: 16515389

6. Ferrari M, Mottola L, Quaresima V. Principles, techniques, and limitations of near infrared spectroscopy. Can J Appl Physiol. 2004; 29: 463–487. https://doi.org/10.1139/h04-031 PMID: 15328595

7. Harper D, Chandler B. Splanchnic circulation. BJA Education. 2016; 16: 66–71.

8. Guyton PW Jr, Karamlou T, Ratnayaka K, El-Said HG, Moore JW, Rao RP. An elusive prize: transcutaneous near infrared spectroscopy (NIRS) monitoring of the liver. Front Pediatr. 2020; 8: 563483. https://doi.org/10.3389/fped.2020.563483 PMID: 33303267

9. Ookawara S, Ito K, Ueda Y, Miyazawa H, Hayasaka H, Kofuji M, et al. Differences in tissue oxygenation and changes in total hemoglobin signal strength in the brain, liver, and lower-limb muscle during hemodialysis. J Artif Organs. 2018; 21: 86–93. https://doi.org/10.1007/s10047-017-0978-1 PMID: 28785828

10. Minato S, Ookawara S, Ito K, Miyazawa H, Hayasaka H, Kofuji M, et al. Differences in cerebral and hepatic oxygenation in response to intradialytic blood transfusion in patients undergoing hemodialysis. J Artif Organs. 2019; 22: 316–323. https://doi.org/10.1007/s10047-019-01118-2 PMID: 31342286

11. Imai S, Ookawara S, Ito K, Kiryu S, Tabei K, Morishita Y. Deterioration of hepatic oxygenation precedes an onset of intradialytic hypotension with little change in blood volume during hemodialysis. Blood Purif. 2018; 45: 345–346. https://doi.org/10.1159/000486232 PMID: 29455201

12. Kitano T, Ito K, Ookawara S, et al. Changes in tissue oxygenation in response to sudden intradialytic hypotension. J Artif Organs. 2020; 23: 187–190. https://doi.org/10.1007/s10047-019-01147-x PMID: 31760517

13. Hongo K, Kobayashi S, Okudera H, Hokama M, Nakagawa F. Noninvasive cerebral optical spectroscopy: depth-resolved measurements of cerebral haemodynamics using indocyanine green. Neuril Res. 1995; 17: 89–93. https://doi.org/10.1080/01616412.1995.11740293 PMID: 7609855

14. Maslehaty H, Krause-Titz U, Petridis AK, Barth H, Mehdom HM. Continuous measurement of cerebral oxygenation with near-infrared spectroscopy after spontaneous subarachnoid hemorrhage. I.S.R.N. Neuroi. 2012; 2012: 907187. https://doi.org/10.5402/2012/907187 PMID: 23209938

15. Ookawara S, Sato H, Takeda H, Tabei K. Methods for approximating colloid osmotic pressure in long-term hemodialysis patients. Ther Apher Dial. 2014; 18: 202–207. https://doi.org/10.1111/1744-9987.12070 PMID: 24720412
16. Prohovnik I, Post J, Uribarri J, Lee H, Sandu O, Langhoff E. Cerebrovascular effects of hemodialysis in chronic kidney disease. J Cereb Blood Flow Metab. 2007; 27: 1861–1869. https://doi.org/10.1038/sj.jcbfm.9600478 PMID: 17406658

17. Hoshino T, Ookawara S, Goto S, Miyazawa H, Ito K, Urda Y, et al. Evaluation of cerebral oxygenation in patients undergoing long-term hemodialysis. Nephron Clin Pract. 2014; 126: 57–61. https://doi.org/10.1159/000358432 PMID: 24526002

18. Ito K, Ookawara S, Ueda Y, Goto S, Miyazawa H, Yamada H, et al. Factors affecting cerebral oxygenation in hemodialysis patients: cerebral oxygenation associates with pH, hemodialysis duration, serum albumin concentration, and diabetes mellitus. PLoS One. 2015; 10: e0117474. https://doi.org/10.1371/journal.pone.0117474 PMID: 25706868

19. Kalantar-Zadeh K, Kopple JD, Kilpatrick RD, McAllister CJ, Shinaberger CS, Gjertson DW, et al. Association of morbid obesity and weight change over time with cardiovascular survival in hemodialysis population. Am J Kidney Dis. 2005; 46:489–500. https://doi.org/10.1053/j.ajkd.2005.05.020 PMID: 16129211

20. Park J, Ahmed SF, Streja E, Molnar MZ, Flegal KM, Gillen D, et al. Obesity paradox in end-stage kidney disease patients. Prog Cardiovasc Dis. 2014; 56: 415–425. https://doi.org/10.1016/j.pcad.2013.10.005 PMID: 24438733

21. Scholze A, Rattensperger D, Zidek W, Tepe I, Low serum leptin predicts mortality in patients with chronic kidney disease stage 5. Obesity. 2007; 15: 1617–1622. https://doi.org/10.1038/oby.2007.191 PMID: 17558000

22. Ko YT, Lin YL, Kuo CH, Lai YH, Wang CH, Hsu BG. Low serum leptin levels are associated with malnutrition status according to malnutrition-inflammation score in patients undergoing chronic hemodialysis. Hemodial Int. 2019; 24: 221–227. https://doi.org/10.1111/1943-9553.12877

23. Nasri H. Serum leptin concentration and left ventricular hypertrophy and function in maintenance hemodialysis patients. Minerva Urol Nefrol. 2006; 58: 189–193. PMID: 16767072

24. Hogas S, Bilha SC, Branistea D, Hogas M, Gazov A, Kanbay M, et al. Potential novel biomarkers of cardiovascular dysfunction and disease: cardiotropin-1, adipokines and galectin-3. Arch Med Sci. 2017; 13: 897–913. https://doi.org/10.5101/ams.2016.58664 PMID: 28721158

25. Dervisevic A, Subo A, Avdagic N, Zaciragic A, Babic N, Fajkic A, et al. Elevated serum leptin level is associated with body mass index but not with serum C-reactive protein and erythrocyte sedimentation rate values in hemodialysis patients. Mater Sociomed. 2015; 27: 99–103. https://doi.org/10.5455/msm.2015.27.99-103 PMID: 26005385

26. Rastegari E, Nasri H. Association of serum leptin with C-reactive protein in hemodialysis patients. J Nephroparmacol. 2012; 1: 19–21. PMID: 28197429

27. Moist LM, Troyanov S, White CT, Wazny LD, Wilson JA, McFarlane P, et al. Canadian Society of Nephrology Commentary on the 2012 KDIGO Clinical Practice Guideline for anemia in CKD. Am J Kidney Dis. 2013; 62: 860–873. https://doi.org/10.1053/j.ajkd.2013.08.001 PMID: 24054466

28. Locatelli F, Barany P, Covic A, De Francesco A, Del Vecchio L, Goldsmith D, et al. ERA-EDTA Advisory Board: kidney disease: improving global outcome guidelines on anaemia management in chronic kidney disease: a European Renal Best Practice position statement. Nephrol Dial Transplant. 2013; 28: 1346–1359. https://doi.org/10.1093/ndt/gft033 PMID: 23585588

29. Yamamoto H, Nishi S, Tomo T, Masakane I, Saito K, Nangaku M, et al. 2015 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease. Ren Replace Ther. 2017; 3: 36.

30. Lautt WW. Mechanism and role of intrinsic regulation of hepatic arterial blood flow: hepatic arterial buffer response. Am J Physiol. 1985; 249: G549–G56. https://doi.org/10.1152/ajpgi.1985.249.5.G549 PMID: 3904482

31. Jakob SM. Clinical review: splanchnic ischaemia. Crit Care. 2002; 6: 306–312. https://doi.org/10.1186/cc1515 PMID: 12225604

32. Jakob SM, Tenhunen JJ, Laitinen S, Heino A, Alhava E, Takala J. Effects of systemic arterial hypoperfusion on splanchnic hemodynamics and hepatic arterial buffer response in pigs. Am J Physiol Gastrointest Liver Physiol. 2001; 280: G819–G827. https://doi.org/10.1152/ajpgi.2001.280.5.G819 PMID: 11925859

33. Vincent JL, De Backer D, Wiedermann CJ. Fluid management in sepsis: The potential beneficial effects of albumin. J Crit Care. 2016; 35: 161–167. https://doi.org/10.1016/j.jcrc.2016.04.019 PMID: 27481753

34. Carvalho JR, Machado MV. New insights about albumin and liver disease. Ann Hepatol. 2018; 17: 547–560. https://doi.org/10.5604/01.3001.0012.0916 PMID: 29893696

35. Bernardi M, Ricci CS, Zaccherini G. Role of human albumin in the management of complications of liver cirrhosis. J Clin Exp Hepatol. 2014; 4: 302–311. https://doi.org/10.1016/j.jceh.2014.08.007 PMID: 25755577
36. Lemes HP, Araujo S, Nascimento D, Cunha D, Garcia C, Queiroz V, et al. Use of small doses of furosemide in chronic kidney disease patients with residual renal function undergoing hemodialysis. Clin Exp Nephrol. 2011; 15: 554–559. https://doi.org/10.1007/s10157-011-0427-z PMID: 21416248

37. Maduell F, Rodas L, Broseta JJ, Gomez M, Font MX, Molina A, et al. High-permeability alternatives to current dialyzers performing both high-flux hemodialysis and postdilution online hemodiafiltration. Artif Organs. 2019; 43:1014–1021. https://doi.org/10.1111/aor.13480 PMID: 31038748

38. Cozzolino M, Magagnoli L, Ciceri P, Conte F, Galassi A. Effect of a medium cut-off (Theranova®) dialyser on haemodialysis patients: a prospective, cross-over study. Clin Kidney J. 2019: 14: 382–389. https://doi.org/10.1093/ckj/sfz155 PMID: 33564442

39. Nitta K, Goto S, Masakane I, Hanafusa N, Taniguchi M, Hasegawa T, et al. Annual dialysis report for 2018, JSST Renal Data Registry: survey methods, facility data, incidence, prevalence, and mortality. Renal Replacement Therapy. 2020; 6: 41.